ClinicalTrials.gg
WithdrawnNCT04173975BELK@CCPUpdated Feb 22, 2022

Validation of the Efficacy and Usability of the BELK Orthosis Knee Module in a Neurological Setting (BELK@CCP)

An interventional study of With knee exoskeleton in Knee Instability, Neuromuscular Diseases and Central Nervous System Diseases, sponsored by Casa di Cura Privata del Policlinico SpA. Withdrawn. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-02-22.

Sponsored by Casa di Cura Privata del Policlinico SpA · Not applicable, Interventional, and Treatment

Why this study was withdrawn
pandemic of coronavirus disease

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Study summary

This present study will be devoted to the first clinical study on the efficacy of the BELK system in enhancing mobility and improve the knee rehabilitation process in people with NeuroMuscular Diseases (NMD) and Central Nervous System (CNS) disorders with knee instability that implies deficit in gait and in locomotion during ADL.

Participants will receive a 6-week training program (3 weeks with the BELK orthosis knee module) in a clinical setting in add-on to the standard neuro-rehabilitation treatment. Gait analysis and Instrumental Test will be performed every week till the end of the six-week training period while the Clinical Scales and Questionnaires will be performed after three weeks and at the end of the training period. Finally, additional outcome measures comprise the scores on the System Usability Scale (SUS) to evaluate the hardware and the Software Usability Measurement Inventory (SUMI) to evaluate the software of the BELK orthosis. These two measures will be administrated at the end of training with Belk orthosis, to rate patients' and operators' (e.g., physical therapist, medical doctors) satisfaction.

During 2018, the company GOGOA (www.gogoa.eu), specialized in design, manufacturing and commercialization of Robotic Assisted Rehabilitation (RAR) systems, has developed a first prototype of the BELK system, a powered wearable robotic device that can be used for knee rehabilitation, in the sub-acute phase of knee injuries. As BELK is a wearable device, it can be used both, by the physiotherapist in the rehabilitation centers, improving the knee rehabilitation process and increasing patients' comfort, and accelerating their rehabilitation process.

Casa di Cura del Policlinico (CCP https://www.ccppdezza.it/en/) is a fully integrated multi-specialty clinical center aiming at providing both inpatient and outpatient services mainly directed to neurological patients. The Center is constituted as a Department of Neuro-rehabilitation Sciences, accredited by the Italian National Health System, and economically supported by Regione Lombardia. CCP offers to chronic neurological patients the highest comprehensive standards of care in a comfortable environment, through a multidisciplinary patient management approach organized around a core rehabilitation program.

Read the detailed description

The study design comprises a clinical study aimed at assessing efficacy of the BELK orthosis knee module on management of instability of the knee in 15 adults who have NMD or a CNS disorder. Participants will receive a 6-week training program (3 weeks with the BELK orthosis knee module) in a clinical setting in add-on at the standard neurorehabilitation treatment.

The add-on rehabilitation training will be focused on lower limb with specific activities for knee instability, and will comprise 3 weeks using the BELK orthosis knee module and 3 weeks without any orthosis. The activities will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).

This clinical study will be a Randomized Control Trial (RCT) crossover longitudinal.

The clinical trial will be split in the following phases :

  • Recruitment. Subjects admitted to CCP Neurorehabilitation unit will be recruited after considering inclusion and exclusion criteria through clinical history and medical visit.
  • Randomization. Enrolled participants will be randomly allocated (per 2 blocked randomization lists, generated electronically by www.random.org) into the BELK assisted group (Group A) or the control group (Group B).
  • Clinical, instrumental and questionnaires assessment at T0 (baseline)
  • Rehabilitation Treatment (first block) three weeks period, all the patients will perform rehabilitation training. The patients allocated in Group A will perform the training wearing the BELK device while patients allocated in Group B will perform the same exercise without any exoskeleton.
  • Clinical, instrumental and questionnaires assessment at T1 (crossover)
  • Rehabilitation Treatment (second block) three weeks period, all the patients will perform rehabilitation training. The patients allocated in Group B will perform the training wearing the BELK device while patients allocated in Group A will perform the same exercise without any exoskeleton.
  • Clinical, instrumental, questionnaires and usability assessment at T2 (final)
  • Additional Instrumental Test will be performed after the first and the second week of each rehabilitation treatment block (i.e., T01, T02, T11, T12).

Instrumental Test consist of:

  • Bio-mechanical performance (gait kinematics/kinetics analysis),
  • Surface electromyography for knee functional evaluation (EMG),
  • 6-minute walking test (6mWT),
  • Baseline assessments uptake (VO2),
  • Hearth rate (HR),
  • Breathing frequency (BF),
  • Timed Up and Go Test (TUG),
  • Stair Climb Test (SCT).

Clinical scales consist of:

  • Functional Independence Measure scale (FIM),
  • Functional Ambulation category scale (FAC),
  • lower-leg Ashworth scale (sum of score for hip, knee and ankle) (AS),
  • Mini Balance Evaluation Systems Test (Mini-Best),
  • Motricity Index (MI),
  • Self-reported perceived effort (CR-10 Borg).

Questionnaires consist of:

  • International Knee Documentation Committee subjective knee evaluation form (IKDC),
  • Knee Outcome Survey Activity of Daily Living (KOS ADL) and health-related quality of life (SF-36).
02

Conditions studied

  • Knee Instability
  • Neuromuscular Diseases
  • Central Nervous System Diseases
  • Stroke
03

In context

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 97 are open to participants now.

Browse Neuromuscular Diseases studies →

Lead sponsor

Casa di Cura Privata del Policlinico SpA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 30 - 85
  • Sex: males and females
  • Diagnosis of Neuromuscular diseases (NMD) or central nervous system (CNS) disorder with knee instability conditioning gait
  • Functional Ambulation Categories (FAC) > 3
  • (MMSE) > 24
  • Ability to walk at least 10 meters alone or with maximum 1 person assistance

Exclusion criteria

Exclusion Criteria:

  • Bilateral impairment of the knees
  • Knee implant
  • Lower extremity amputation
  • Severe sensorial impairment of the lower limbs
  • Legal blindness or severe visual impairment
  • Pacemakers or metal implants
  • Refusal to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    With knee exoskeleton

    The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working). Each session will be 45 minutes long. Three time per week, for three weeks. The patients allocated in this arm will perform the training wearing the BELK device.

    Device: With knee exoskeleton

  • No intervention
    Without exoskeleton

    The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working). Each session will be 45 minutes long. Three time per week, for three weeks. The patients allocated in this arm will perform the training without any exoskeleton.

Interventions

  • DeviceWith knee exoskeleton

    BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.

06

What researchers measure

Primary outcomes

  1. Change in walking velocity

    Walking velocity \[m/s\] will be calculated during walk test (10MWT). Markers positioned on the body will be tracked through a motion capture software and analyzed.

    Time frame: Before and Immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  2. Change in Gait Profile Score

    Gait Profile Score (GPS) is a useful index to analyze the gait performances. It is calculated starting from fifteen Gait Variable Score (GVS) which give a deeper view on the variables related to the locomotion trials.

    Time frame: Before and Immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

Secondary outcomes

  1. Change in 6-minute walking test (6MWT)

    The six-minute walk test (6MWT) measures the distance, in meters, that an individual is able to walk over a total of six minutes on a hard, flat surface.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  2. Change in joint force

    Joint forces will be calculated as the amount of pressure recorded in newtons on the force plates during walking tests.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  3. Change in Surface electromyography (sEMG)

    Surface electromyography (sEMG) is a non-invasive procedure involving the detection, recording and interpretation of the electric activity of groups of muscles at rest (i.e., static) and during activity (i.e., dynamic). The procedure is performed using a single or an array of electrodes placed on the skin surface over the muscles to be tested. Recording can also be made using a hand-held device, which is applied to the skin surface at different sites. Electrical activity is assessed by computer analysis of the frequency spectrum, amplitude, or root-mean-square of the electrical action potential.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  4. Change in energy cost of walking

    Energy cost of walking, expressed in ml O2/kg/m will be measured using indirect calorimetry device

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  5. Change in Stair Climb Test (SCT)

    The Stair Climb Test (SCT) measures, in seconds, the time taken by an individual to ascend and descend 10 steps (each step is 0.18 m in height).

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  6. Change in Timed Up and Go test (TUG)

    The Timed "Up and Go" Test measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm, arm height 65 cm), walk a distance of 3 meters (approximately 10 feet), turn, walk back to the chair, and sit down.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  7. Change in Short Form Survey Instrument (SF36)

    Confidence levels will be calculated using the Short Form Survey Instrument (SF36). Items are scored using Likert scale and yes/no options. Scales are standardized with a scoring algorithm to obtain a score ranging from 0-100. High scores indicate better health status.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  8. Change in International Knee Documentation Committee (IKDC) Questionnaire

    The IKDC Questionnaire is a subjective scale that provides patients with an overall function score. The questionnaire looks at 3 categories: symptoms, sports activity, and knee function. Symptoms sub scale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee. Meanwhile, the sports activity sub scale focuses on functions like going up and down the stairs, rising from a chair, squatting and jumping. The knee function sub scale asks patients one simple question: how is their knee at present versus how was their knee prior to injury? Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function.

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  9. Change in Knee Outcome Survey (KOS)

    The Knee Outcome Survey (KOS) is a patient-completed questionnaire that provides a percentage of disability during every day activities (activities of daily living sub scale) or sports (sports activity sub scale). The lower the percentage, the higher the disability. This is a self-report measure that is broken down into two categories (ADLs and sport activities) that rates perceived disability with 5 being "no difficulty" and 0 being "unable to perform".\[1\]

    Time frame: Before and immediately after the rehabilitation training of each arm (Initial, after 3 weeks and final)

  10. System Usability Scale (SUS)

    The scores on the System Usability Scale (SUS) was measured in order to assess the usability of BELK during rehabilitation training

    Time frame: Immediately after the rehabilitation training of experimental arm.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2021; primary completion for Mar 2021, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 22, 2019
StartEst.
Jan 1, 2021
Primary completionEst.
Mar 31, 2021
CompletionEst.
Aug 31, 2021
Last update
Feb 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04173975
Lead sponsor
Casa di Cura Privata del Policlinico SpA
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Jan 1, 2021 (estimated)
Primary completion
Mar 31, 2021 (estimated)
Completion
Aug 31, 2021 (estimated)
Last update
Feb 22, 2022

Study contacts

Peppino Tropea, PhD
principal investigator · Casa di Cura Privata del Policlinico SpA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion